false
0001716947
0001716947
2024-08-14
2024-08-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): August 14, 2024 (August 14, 2024)
Ensysce
Biosciences, Inc.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-38306 |
|
82-2755287 |
(State
or other jurisdiction of
incorporation
or organization) |
|
(Commission
File
Number) |
|
(I.R.S.
Employer
Identification
Number) |
7946
Ivanhoe Avenue, Suite 201
La
Jolla, California |
|
92037 |
(Address
of principal executive offices) |
|
(Zip
Code) |
(858)
263-4196
Registrant’s
telephone number, including area code
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock, par value $0.0001 per share |
|
ENSC |
|
The
Nasdaq Stock Market LLC |
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
2.02. Results of Operations and Financial Condition.
On
August 14, 2024, Ensysce Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the
fiscal quarter ended June 30, 2024. A copy of the press release is included as Exhibit 99.1 to this Current Report on Form 8-K.
The
information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed to be “filed” for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended, nor will they be deemed to be incorporated by reference in any filing
under the Securities Act of 1933, as amended, except as will be expressly set forth by specific reference in such a filing.
Forward-Looking
Statements
This
report contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. These statements may be made directly in this report. Some of the forward-looking
statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the words “anticipate,”
“expect,” “suggests,” “plan,” “believe,” “intend,” “estimates,”
“targets,” “projects,” “should,” “could,” “would,” “may,” “will,”
“forecast” and other similar expressions are intended to identify forward-looking statements. All forward-looking statements
are based upon management estimates and forecasts and reflect the views, assumptions, expectations, and opinions of the Company as of
the date of this report, and may include, without limitation, changes in general economic and political conditions, all of which are
accordingly subject to change. Any such estimates, assumptions, expectations, forecasts, views or opinions set forth in this report constitute
the Company’s judgments and should be regarded as indicative, preliminary and for illustrative purposes only. The forward-looking
statements and projections contained in this report are subject to a number of factors, risks and uncertainties, some of which are not
currently known to the Company, that may cause the Company’s actual results, performance or financial condition to be materially
different from the expectations of future results, performance of financial condition. Although such forward-looking statements have
been made in good faith and are based on assumptions that the Company believes to be reasonable, there is no assurance that the expected
results will be achieved. The Company’s actual results may differ materially from the results discussed in forward-looking statements.
Additional information on factors that may cause actual results and the Company’s performance to differ materially is included
in the Company’s filings with the Securities and Exchange Commission (the “SEC”). Copies of such filings with the SEC
are available publicly on the SEC’s website at www.sec.gov or may be obtained by contacting the Company. Readers are cautioned
not to place undue reliance upon any forward-looking statements, which speak only as of the date made. These forward-looking statements
are made only as of the date hereof, and the Company does not undertake any obligations to update or revise the forward-looking statements,
whether as a result of new information, future events or otherwise, except as required by law.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
Dated:
August 14, 2024 |
Ensysce
Biosciences, Inc. |
|
|
|
By: |
/s/
Lynn Kirkpatrick |
|
Name: |
Dr.
Lynn Kirkpatrick |
|
Title: |
President
and Chief Executive Officer |
|
|
(Principal
Executive Officer) |
Exhibit 99.1
Ensysce Biosciences Reports Second Quarter 2024
Financial Results
PF614-MPAR Progressing to Phase 1b Study to Verify
Both Overdose Protection and Effective Delivery of Oxycodone
Opioid Use Disorder Program Advances with Selection
of PF9001 as Lead Drug Candidate
PF614 Phase 3 Protocol Being Finalized for Submission
to FDA
SAN DIEGO, CA / August 14, 2024 / Ensysce Biosciences,
Inc. (NASDAQ: ENSC) (“Ensysce” or the “Company”), a clinical-stage pharmaceutical company developing innovative
solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today reported financial and operational
results for the second quarter ended June 30, 2024.
Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce,
commented, “Our FDA-designated Breakthrough Therapy product candidate, PF614-MPAR, is a game-changer for Ensysce as we progress
to a second clinical trial, PF614-MPAR-102. We have re-engaged Quotient Sciences to prepare our Phase 1b protocol which will utilize their
Translational Pharmaceutics® platform to manufacture and test the PF614-MPAR drug product to expedite the completion of this clinical
study.
Additionally, an important breakthrough emerged in
our opioid use disorder (OUD) program with the identification of our lead candidate, PF9001. Our OUD program is designed to provide a
safer product for those suffering from OUD and is supported by an ongoing multi-year National Institutes of Health (NIH) award.”
Dr. Kirkpatrick concluded, “Looking ahead,
with our PF614 Phase 3 clinical trial on track to initiate in the second half of this year, we are finalizing the Phase 3 protocol design
and preparing for site selection in the coming months. The favorable data generated from our prior PF614 clinical studies verified that
PF614 delivers oxycodone in a manner equivalent to a commercially available opioid and provides pain relief with reduced abuse potential.
Our goal is to provide safe and effective TAAPTM and MPAR® products and differentiate PF614 and PF614-MPAR
from the current slate of extended-release opioid analgesics, as evidenced from the data we have generated over the last year.”
TAAPTM
(Opioid Abuse Deterrent Program) Update
Our lead product, PF614, is a Trypsin-Activated Abuse
Protection (TAAPTM) extended-release oxycodone and a potential “next generation” analgesic for severe pain. The
Company’s TAAPTM technology is designed to control release, be highly resistant to tampering, and reduce abuse through
a unique chemical modification. PF614’s TAAPTM modification makes it inactive until it is swallowed, following which
it is activated or “turned on” to release oxycodone by the body’s own trypsin, an enzyme in the small intestine. Regulatory
submissions and meetings were held in early 2024 and a Phase 3 trial is planned to initiate in the second half of 2024.
MPAR® (Opioid Abuse Deterrent and
Overdose Protection Program) Update
PF614-MPAR is a combination product of the TAAPTM
prodrug PF614 with a trypsin inhibitor, designed to treat severe pain while providing overdose protection. MPAR®
(Multi-Pill Abuse Resistance) reduces or “turns off” the release of the opioid to prevent an overdose, providing an additional
layer of protection to Ensysce’s TAAP™ medications. Over the past year, clinical data demonstrated that the MPAR®
technology reduces release and absorption of oxycodone from PF614 when consumed in more than a prescribed dose, leading to the
FDA’s recognition and Breakthrough Therapy designation. The Company’s upcoming Phase 1b study, PF614-MPAR-102, will test
multiple PF614-MPAR drug products to verify both overdose protection and effective delivery of oxycodone across a dosage range.
Opioid Use Disorder (OUD) Program Update
In June, the Company achieved a critical milestone
in the OUD program with the selection of lead drug candidate PF9001, designed to provide a safer and more effective way to help those
suffering from the effects of opioid use. PF9001, designed with the application of Ensysce’s TAAPTM platform to reduce
the abuse profile, has demonstrated a lower potential for cardiovascular side effects associated with traditional methadone OUD treatments.
The program is continuing to advance to Investigational New Drug (IND) enabling studies. In coordination with advancement of the OUD program,
the Company announced an agreement with Purisys LLC to scale the manufacture of PF9001. This OUD work has been supported by a multi-year
Helping to End Addiction Long-Term (HEAL) award of up to $15 million granted by the NIH and the National Institute on Drug Abuse (NIDA).
Q2 2024 Financial Results
Cash – Cash and cash equivalents were
$1.0 million as of June 30, 2024, compared to $1.1 million as of December 31, 2023.
Federal Grants – Funding under federal
grants totaled to $0.2 million for the second quarter of 2024 compared to $0.5 million in the comparable year ago quarter. The difference
is due to the completion of funding under the MPAR grant in December 2023.
Research & Development Expenses –
R&D expenses were $0.9 million for the second quarter of 2024 compared to $1.6 million for the same period in 2023. The decrease of
$0.7 million was primarily due to reduced external research and development costs related to clinical and pre-clinical programs for PF614
and PF614-MPAR.
General & Administrative Expenses – G&A
expenses were $1.2 million in the second quarter of 2024, generally in line with $1.1 million for the second quarter of 2023.
Other Income (Expense) – Total other
income (expense), net, was an expense of approximately $12,000 for the second quarter of 2024 compared to income of approximately $55,000
for the same period of 2023. The changes in other expenses were primarily due to interest expense and non-cash fair value adjustments
for warrants.
Net Loss – Net loss attributable to common
stockholders for the second quarter of 2024 was $2.0 million compared to $2.2 million for the second quarter of 2023. As a clinical stage
biotech company, our continued research and development efforts toward regulatory approvals for our product candidates are expected to
result in losses for the foreseeable future.
About Ensysce Biosciences
Ensysce Biosciences is a clinical-stage company using
its proprietary technology platforms to develop safer prescription drugs. Leveraging its Trypsin-Activated Abuse Protection (TAAP™)
and Multi-Pill Abuse Resistance (MPAR®) platforms, the Company is developing unique, tamper-proof treatment options for pain that
minimize the risk of both drug abuse and overdose. Ensysce’s products are anticipated to provide safer options to treat patients
suffering from severe pain and assist in preventing deaths caused by medication abuse. The platforms are covered by an extensive worldwide
intellectual property portfolio for a wide array of prescription drug compositions. For more information, please visit www.ensysce.com.
Definitions
TAAP: trypsin activated abuse protection - designed
to protect against prescription drug abuse.
MPAR: multi-pill abuse resistance - designed to protect
against abuse and accidental overdose.
Forward-Looking Statements
Statements contained in this press release that are
not purely historical may be deemed to be forward-looking statements for the purposes of the safe harbor provisions under The Private
Securities Litigation Reform Act of 1995 and other federal securities laws. Without limiting the foregoing, the use of words such as “may,”
“intends,” “can,” “might,” “will,” “expect,” “plan,” “possible,”
“believe” and other similar expressions are intended to identify forward-looking statements. The product candidates discussed
are in clinic and not approved and there can be no assurance that the clinical programs will be successful in demonstrating safety and/or
efficacy, that Ensysce will not encounter problems or delays in clinical development, or that any product candidate will ever receive
regulatory approval or be successfully commercialized. All forward-looking statements are based on estimates and assumptions by Ensysce’s
management that, although Ensysce believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks
and uncertainties that may cause actual results to differ materially from those that Ensysce expected. In addition, Ensysce’s business
is subject to additional risks and uncertainties, including among others, possible NASDAQ delisting, the initiation and conduct of preclinical
studies and clinical trials; the timing and availability of data from preclinical studies and clinical trials; expectations for regulatory
submissions and approvals; potential safety concerns related to, or efficacy of, Ensysce’s product candidates; the availability
or commercial potential of product candidates; the ability of Ensysce to fund its continued operations, including its planned clinical
trials; the dilutive effect of stock issuances from our fundraising; and Ensysce’s and its partners’ ability to perform under
their license, collaboration and manufacturing arrangements. These statements are also subject to a number of material risks and uncertainties
that are described in Ensysce’s most recent quarterly report on Form 10-Q and current reports on Form 8-K, which are available,
free of charge, at the SEC’s website at www.sec.gov. Any forward-looking statement speaks only as of the date on which it was made.
Ensysce undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future
events or otherwise, except as required under applicable law.
Ensysce Biosciences Company Contact:
Lynn Kirkpatrick, Ph.D.
Chief Executive Officer
(858) 263-4196
Ensysce Biosciences Investor Relations Contact:
Shannon Devine
MZ North America
Main: 203-741-8811
ENSC@mzgroup.us
Ensysce Biosciences, Inc.
Condensed Consolidated Statements of Operations
(Unaudited)
| |
Three Months Ended June 30, | | |
Six Months Ended June 30, | |
| |
2024 | | |
2023 | | |
2024 | | |
2023 | |
Federal grants | |
$ | 181,797 | | |
$ | 490,472 | | |
$ | 487,519 | | |
$ | 1,280,107 | |
Operating expenses: | |
| | | |
| | | |
| | | |
| | |
Research and development | |
| 947,229 | | |
| 1,643,726 | | |
| 1,726,133 | | |
| 3,349,742 | |
General and administrative | |
| 1,190,010 | | |
| 1,140,700 | | |
| 2,559,791 | | |
| 2,695,553 | |
Total operating expenses | |
| 2,137,239 | | |
| 2,784,426 | | |
| 4,285,924 | | |
| 6,135,295 | |
Loss from operations | |
| (1,955,442 | ) | |
| (2,293,954 | ) | |
| (3,798,405 | ) | |
| (4,855,188 | ) |
Total other income (expense), net | |
| (12,351 | ) | |
| 54,652 | | |
| (1,285,951 | ) | |
| 424,080 | |
Net loss | |
$ | (1,967,793 | ) | |
$ | (2,239,302 | ) | |
$ | (5,084,356 | ) | |
$ | (4,431,108 | ) |
Adjustments to net loss | |
| — | | |
| 3,331 | | |
| (216 | ) | |
| (1,037 | ) |
Net loss attributable to common stockholders | |
$ | (1,967,793 | ) | |
$ | (2,235,971 | ) | |
$ | (5,084,572 | ) | |
$ | (4,432,145 | ) |
Net loss per share attributable to common stockholders, basic and diluted | |
$ | (0.22 | ) | |
$ | (0.98 | ) | |
$ | (0.67 | ) | |
$ | (2.66 | ) |
Ensysce Biosciences, Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited)
| |
Six Months Ended June 30, | |
| |
2024 | | |
2023 | |
Net cash used in operating activities | |
$ | (5,718,294 | ) | |
$ | (6,715,461 | ) |
Net cash provided by financing activities | |
| 5,637,921 | | |
| 7,397,241 | |
Change in cash and cash equivalents | |
| (80,373 | ) | |
| 681,780 | |
Cash and cash equivalents at beginning of period | |
| 1,123,604 | | |
| 3,147,702 | |
Cash and cash equivalents at end of period | |
$ | 1,043,231 | | |
$ | 3,829,482 | |
Ensysce Biosciences, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
| |
June 30, | | |
December 31, | |
| |
2024 | | |
2023 | |
Assets | |
| | | |
| | |
Current assets: | |
| | | |
| | |
Cash and cash equivalents | |
$ | 1,043,231 | | |
$ | 1,123,604 | |
Prepaid expenses and other current assets | |
| 1,416,506 | | |
| 1,165,264 | |
Total current assets | |
| 2,459,737 | | |
| 2,288,868 | |
Other assets | |
| 335,883 | | |
| 419,217 | |
Total assets | |
$ | 2,795,620 | | |
$ | 2,708,085 | |
| |
| | | |
| | |
Liabilities and stockholders’ equity (deficit) | |
| | | |
| | |
Current liabilities: | |
| | | |
| | |
Accounts payable | |
$ | 481,971 | | |
$ | 1,936,007 | |
Accrued expenses and other liabilities | |
| 370,186 | | |
| 542,260 | |
Notes payable and accrued interest | |
| 454,463 | | |
| 854,697 | |
Total current liabilities | |
| 1,306,620 | | |
| 3,332,964 | |
Long-term liabilities | |
| 9,615 | | |
| 26,388 | |
Total liabilities | |
| 1,316,235 | | |
| 3,359,352 | |
Stockholders’ equity (deficit) | |
| 1,479,385 | | |
| (651,267 | ) |
Total liabilities and stockholders’ equity (deficit) | |
$ | 2,795,620 | | |
$ | 2,708,085 | |
v3.24.2.u1
Cover
|
Aug. 14, 2024 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Aug. 14, 2024
|
Entity File Number |
001-38306
|
Entity Registrant Name |
Ensysce
Biosciences, Inc.
|
Entity Central Index Key |
0001716947
|
Entity Tax Identification Number |
82-2755287
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
7946
Ivanhoe Avenue
|
Entity Address, Address Line Two |
Suite 201
|
Entity Address, City or Town |
La
Jolla
|
Entity Address, State or Province |
CA
|
Entity Address, Postal Zip Code |
92037
|
City Area Code |
(858)
|
Local Phone Number |
263-4196
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common
Stock, par value $0.0001 per share
|
Trading Symbol |
ENSC
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14a -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Ensysce Biosciences (NASDAQ:ENSC)
Historical Stock Chart
From Jul 2024 to Aug 2024
Ensysce Biosciences (NASDAQ:ENSC)
Historical Stock Chart
From Aug 2023 to Aug 2024